Categories Earnings, Other Industries

United Therapeutics, MannKind to co-develop pulmonary hypertension drug

The healthcare sector this week witnessed yet another instance of two companies coming together to find therapeutic solution for a challenging medical condition. Biotechnology firm United Therapeutics (UTHR) has joined hands with California-based drug developer MannKind Corp. (MNKD) to co-develop a formulation of treprostinil, which is being evaluated for the treatment of pulmonary arterial hypertension.

Under the exclusive licensing and collaboration agreement, the companies will jointly commercialize the dry powder formulation globally. United Therapeutics will make an upfront payment of $45 million to MannKind, which will be followed up with payments of about $50 million on achieving certain milestones. The deal also includes the payment of royalty to MannKind on product sales.

The responsibilities of United Therapeutics will be to develop the drug, ensure regulatory compliance and commercial activities. The clinical supplies and initial commercial supplies of the product will be manufactured by MannKind.

Under the exclusive agreement, the companies will jointly commercialize the dry powder formulation globally

United Therapeutics has an option to include other ingredients used in the treatment of pulmonary hypertension on payment of $40 million to MannKind for each product. In addition, the companies signed a pact for carrying out research on other products that do not come under the licensing agreement.

Earlier this year, MannKind completed the phase-I of its clinical study on Treprostinil Technosphere, achieving the primary endpoint. Based on the positive outcome of the preliminary trial, the company launched phased-II of the study to evaluate its safety in pulmonary hypertension patients.

RELATED: Teva Pharma secures FDA approval

“We are pleased with this new opportunity to demonstrate the value of our drug and device combination platform for delivering therapeutic products. We believe this collaboration will have the potential to significantly improve the lives of people living with pulmonary arterial hypertension,” said MannKind CEO Michael Castagna.

Pulmonary arterial hypertension is a condition characterized by high blood pressure in the arteries running between the lungs and heart of the patient. If left untreated, the disease could lead to heart failure.

Following the announcement, MannKind stock jumped about 40% in premarket trading, after closing the last trading session slightly lower. Shares of United Therapeutics, which dropped about 19% over the past eight months, closed the last trading session down 1%.

RELATED: Merck, others to lower drug prices

Most Popular

Does Unity Software (U) stock has more room to run?

Last month, the IPO market was in a full swing. IPOs of Snowflake (NYSE: SNOW) and JFROG (NASDAQ: FROG) had an impressive opening day in September, the former creating a

PepsiCo (PEP): Steady snacking habits amid pandemic drive strong quarter for beverage giant

PepsiCo Inc. (NASDAQ: PEP) beat market expectations on both revenue and earnings for the third quarter of 2020. The company saw the momentum continue in its snacks business while the

Does the virus-driven boom make Electronic Arts (EA) a good investment?

With more and more people turning to virtual entertainment sources, amid the virus-related movement restrictions, video game publishers like Electronic Arts (NASDAQ: EA) are witnessing unusually high demand. Not surprisingly,

One thought on “United Therapeutics, MannKind to co-develop pulmonary hypertension drug

Comments are closed.

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top